1-5 of 5
Jessica E. Hutti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Roger M. Lyons, Wei-Han Cheng, Laura Moore-Schiltz, Ping Shi, Anders Svensson, Cat N. Bui, Jessica E. Hutti, Ann Marie McNeill, Elizabeth S. Mearns, Archibong Yellow-Duke, Ira Zackon
Journal: Blood
Blood (2022) 140 (Supplement 1): 6938–6939.
https://doi.org/10.1182/blood-2022-163098
Published: 2022
Journal Articles

A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Kimberley Dilley, MD MPH, Jason Harb, PhD, Muhammad Jalaluddin, PhD, Jessica E. Hutti, PhD, Jalaja Potluri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8.
https://doi.org/10.1182/blood-2020-139247
Published: 2020
Journal Articles

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)

Jalaja Potluri, MD, Jason Harb, PhD, Abdullah A. Masud, PhD, Jessica E. Hutti, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139758
Published: 2020
Journal Articles

The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Jacqueline S. Garcia, MD, Jalaja Potluri, MD, Leanne Holes, BS, MBA,, Jason Harb, PhD, Paul Jung, PhD, Jessica E. Hutti, PhD, Josef T. Prchal, MD, Srdan Verstovsek, MD PhD, Claire Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-136938
Published: 2020
Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 55–57.
https://doi.org/10.1182/blood-2020-139492
Published: 2020